INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) | MicrobiomeTrials← Back to trialsNCT07429266
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-05-25Est. Completion: 2028-09
Enrollment target: 250 participants Locations- Regis Clinical Research LLC., Miami, Florida, United States
Other microbiome trials you might be interested in
Polycythemia Vera (PV)Myelofibrosis (MF)Myeloproliferative Neoplasms (MPNs)Post-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPrimary Myelofibrosis (PMF)
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmaco…
Denver, United StatesEst. completion Apr 2028
Primary MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Post-polycythemia Vera Myelofibrosis
This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patient…
Salt Lake City, United StatesCompleted Aug 16, 2023
Primary MyelofibrosisSecondary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisAnemiaMyelofibrosis; AnemiaMyelofibrosis
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor researc…
Multiple Locations, GermanyEst. completion Sep 2031